Tag: transarterial chemoembolization
Y-90 glass microspheres demonstrate cost-effectiveness over TACE in HCC
An economic analysis presented by Laura Crocetti (University of Pisa, Pisa, Italy) in collaboration with several Italian centres including the Bocconi University, University of...
First release RETNET data show no difference in progression-free survival between...
New data from a prospective, multicentre randomised controlled trial show similar hepatic progression-free survival (hPFS) using bland transarterial embolization (TAE) or transarterial chemoembolization (TACE)...
New analysis benchmarks survival rates in unresectable intrahepatic cholangiocarcinoma patients undergoing...
Updating on a previous meta-analysis, new data which pooled survival estimates of patients undergoing transarterial radioembolization (TARE) has shown the treatment to be a...
‘A new narrative’: TACE in the age of Y90 and immunotherapy
Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...
HKUMed discovers new trimodality therapy for locally advanced liver cancer
A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...
Conventional transarterial chemoembolization more cost-effective than drug-eluting embolic TACE
Compared with doxorubicin-loaded drug-eluting embolic transarterial chemoembolization (DEE-TACE), conventional transarterial chemoembolization (cTACE) yielded a higher number of quality-adjusted life years (QALY) at a lower...
International survey reveals high variability in TACE technique
Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...
